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Ronald F. Dorfman (1923-2012), an Emeritus 
Professor of Pathology at the Stanford University 
School of Medicine, had significant input in advancing 
the study of diseases of hematopoietic cells and the 
lymph nodes, which included identifying a disease 
that has been named after him. Dr. Dorfman was 
one of the founders of the field of Hematopathology, 
and, with Dr. Costan Berard, founded the Society 
of Hematopathology in 1981, serving as its 
president from 1982 through 1984, and published a 
classification of non-Hodgkin lymphomas in 1974,1 
which was a variant of the Rappaport classification.2
Dr. Dorfman was born in Johannesburg, 
South Africa, on March 14, 1923 and studied 
medicine at the University of the Witwatersrand. 
From 1944 to 1946 his medical studies were 
suspended due to his military service during World 
War II. In 1948, he received his medical degree and 
completed medical and surgical internships and 
residencies at the Johannesburg General Hospital. 
After that, he went to England, to obtain his MD in 
Internal Medicine at the Royal Postgraduate Medical 
School and Hammersmith Hospital. At one point, he 
concluded that clinical medicine was not his passion 
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and switched to pathology, initially in London and 
subsequently at the South African Institute for 
Medical Research (SAIMR) in Johannesburg. 
During his nine years of working there, his interest 
in the lymphoreticular system was stimulated by 
Dr. George Oettlé, who was the head of the South 
African National Cancer Institute at that time.
During the early 1960s at the SAIMR, Dr. 
Dorfman came across two very unusual cases. The 
patients were African boys, aged 9 and 19, presenting 
enlarged lymph nodes in the neck, producing a “bull-
neck” appearance. The oldest patient’s disease had 
started 10 years earlier, and the disease followed 
a stable course. The histological appearance was 
so uncommon that the slides were submitted to 
several consultants in England, including Dr. Alistair 
Robb-Smith at Oxford University and Professor 
Donald Harrison at the Postgraduate Medical 
School of London. Varied opinions included “an 
unusual reaction to an undetermined infectious 
agent,” a cholesterol-type lipidosis, and even a form 
of Letterer-Siwe disease. In a fascinating article 
published recently by Dr. Dorfman in a periodical 
of the Adler Museum of Medicine, University of 
the Witwatersrand, Johannesburg, he described 
in detail the identification of this rare and intriguing 
disease.3
In 1963, due to his opposition to a society 
that established the superiority of white races over 
the black people of South Africa, he immigrated 
with his family to St. Louis, Missouri, USA, as 
Assistant Professor in the Surgical Pathology 
Division of the Department of Pathology at the 
Washington University School of Medicine, invited 
by Dr. Lauren V. Ackerman. While working there, 
one day a surgical pathology fellow named Juan 
Rosai, born in Poppi, Italy, came to his office with 
slides of two peculiar cases, which he identified 
among a series of cases he had been studying, 
including lymph node biopsies with the diagnosis 
of “malignant reticuloendotheliosis” – a generic 
term embracing malignant disorders of the so-
called reticuloendothelial system. The patients 
were a boy and a girl, both 7 months old presenting 
enlarged painless cervical lymph nodes. The two 
doctors studied the slides of these cases as well 
as those from Dr. Dorfman’s two patients from 
Johannesburg, and immediately agreed that they 
were dealing with the same disease. Reviewing the 
literature, Dr. Rosai found two more cases with great 
clinical and histological similarities to theirs.4,5 They 
prepared and submitted the first description of the 
entity they named “sinus histiocytosis with massive 
lymphadenopathy (SHML): a newly recognized 
benign clinicopathologic entity”.6
The publication stimulated a great deal of 
interest and by the end of 1971 they had collected 
30 new cases received in consultation, motivating 
their second paper with detailed analysis of their 
34 cases, establishing the validity of SHML as a 
definitive clinicopathologic entity.7 They described 
the histological features in early and advanced 
phases of the disease, and called attention to the 
most conspicuous feature, seen in greater or lesser 
degree in every case: the presence of apparently 
viable hematopoietic cells (mostly lymphocytes) 
within extremely large cells, with abundant, clear, 
granular or finely vacuolated cytoplasm and large, 
round, vesicular nuclei containing distinct nucleoli. 
Later, histochemical and immunophenotypic studies 
were able to support these large cells as having the 
features of histiocytes and activated monocytes/
macrophages.8 They differed from reactive sinus 
histiocytes by virtue of their strong staining for S100 
protein. In addition, they differed from Langerhans 
cell histiocytes in that they failed to express CD1a 
antigen, and they do not have Birbeck´s granules at 
the electron microscopy. The other peculiar finding 
was the presence of dozens of lymphocytes located 
within cytoplasmic vacuoles, which most probably 
represented the ability of these cells to enter and 
leave the histiocytic cytoplasm without undergoing 
degenerative changes, a phenomenon known 
as emperipolesis (from the Greek: em = inside, 
peri = around, polesis = going about). They further 
emphasized the essentially benign nature of the 
disease and the capacity of this disorder to clinically 
simulate a malignant process.
It was in 1973 that a group of Spaniards 
published a paper using the eponym Rosai-Dorfman 
for the first time, and from that time this name was 
adopted by many others, particularly for those cases 
where the disease was exclusively extranodal.9
Dr. Rosai, who had been appointed Head 
of Anatomic Pathology at Yale University in New 
Haven, Connecticut, USA, created an archive 
of all the cases of SHML he was aware of, first 
at Minnesota and after at Yale. As an increasing 
number of cases were sent to Dr. Rosai and Dr. 
Dorfman in consultation over the ensuing years, 
they began to appreciate that SHML affected not 
only lymph nodes but also many different extranodal 
sites, at times without lymph node involvement. 
The most prominent extranodal manifestations 
were observed in the skin and soft tissues, upper 
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respiratory tract, bone, genitourinary system, lower 
respiratory tract, and oral cavity, but nowadays the 
literature has shown that this disease can occur 
anywhere.
In 1990, the editor of Seminars in Diagnostic 
Pathology decided to devote an entire issue of the 
journal to a review of the clinical and pathological 
features of 423 cases of extranodal SHML.10
Nowadays, the cause of Rosai-Dorfman 
disease is still unknown. It is suspected that it may 
be of viral etiology and that minor upper respiratory 
tract infections may stimulate the characteristic 
interaction between lymphocytes, the unique 
histiocytes and plasma cells, resulting in massive 
lymphadenopathy and the widespread extranodal 
lesions of this disorder. There is no specific 
treatment for Rosai-Dorfman disease and the 
lesions are not responsive to antibiotics. Treatment 
is not necessary in most cases and enlarged lymph 
nodes usually resolve spontaneously; however, 
some patients may require surgery, radiation 
therapy and/or chemotherapy because of severe 
disease manifestations.
A month before his death, Dr. Dorfman went 
to the Stanford Department of Pathology to give his 
opinion on an unusually difficult example of Rosai-
Dorfman disease. I wondered what comments he 
would make about the challenging case of SHML 
presented in this issue of Autopsy and Case Reports. 
As in this case, a series of 14 deaths occurring in 
the SHML registry were described, and it was noted 
that many of these patients had had immunologic 
and/or hematologic abnormalities.11,12
“Ron Dorfman was considered a gifted 
diagnostician, teacher, and researcher, but those 
who knew him well were equally impressed by 
his warmth. He was considered a consummate 
gentleman and scholar.” These were the words of 
Dr. Stacey E. Mills, Editor-in-Chief of The American 
Journal of Surgical Pathology at the time of Dr. 
Dorfman’s death last June.
Beyond the enigmatic disease of Rosai-
Dorfman, we hope that this brief overview of Dr. 
Dorfman’s life can inspire many young pathologists 
around the world to be good observers, to seek the 
answers to their questions, and to practice medicine 
with humanity and passion.
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